Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.## The healthcare industry is facing various challenges, including nursing homes suing to block a staffing mandate, healthcare organizations not being prepared for cyberattacks, the impact of Ascension's cyberattack, and a house committee targeting healthcare consolidation. Trends in addressing social determinants of health and site-neutral payments are also discussed. A report shows that over a third of healthcare organizations lack a cyberattack contingency plan. Stay informed on healthcare news and trends through the Healthcare Dive newsletter.## Data-driven marketing strategies are crucial for success in today's competitive landscape. Marketers are using data to optimize campaigns and gain insights into consumer behavior. Examples include Pop-Tarts Bites using data to improve ad recall and engagement rates. Legacy media investing in connected TV, retail media convergence, the impact of cookie deprecation on marketing strategies, and the latest trends in marketing data are also covered. Marketing Dive delivers this content to subscribers as part of their newsletter subscription.## AstraZeneca aims to expand its cancer drug sales, while Pfizer and Lilly enter the direct-to-consumer market online. The European Commission declines to revoke approval of PTC Duchenne drug, calling for a new review. Amgen's drug for tough-to-treat lung cancer receives FDA approval, and Regeneron faces new biosimilar threats. An AI biotech has laid off staff, with companies focusing on immune disease research and treatments. Moderna wins a patent dispute, Walgreens and CVS rethink their pharmacy business, and weight-loss drug shortages affect patients. Biopharma Dive provides news and insights on biotech and pharma trends.## AstraZeneca plans to achieve $80 billion in annual revenue by 2030, launching 20 new drugs before the end of the decade. Bio lays off 30 employees as Congress moves forward with the Biosecure Act. Lilly signs a potential $1.1 billion deal with Aktis Oncology for radiopharmaceuticals, GSK's long-acting asthma drug shows positive results in Phase III trials, FDA approves interchangeable biosimilars to Regeneron's Eylea, strong Phase III data for Dupixent by Sanofi and Regeneron, and AltruBio raises $225 million in Series B funding.## AstraZeneca invests $1.5 billion in an antibody-drug conjugate (ADC) manufacturing plant in Singapore. The global market for GLP-1 receptor agonists is projected to reach $125 billion by 2033. Gilead highlights positive results for a liver disease drug, while Rapport Therapeutics and Telix Pharma file for IPOs. Sino Biological offers recombinant cytokines for cell culture research. Bayer announces 1,500 layoffs as part of a company overhaul.## Humana CEO Bruce Broussard steps down on July 1, with current COO Jim Rechtin taking over. Inpatient admissions boost revenue for for-profit providers in Q1. The US increases tariffs on medical products from China to boost domestic production. Black Basta ransomware targets critical infrastructure providers, causing concern among authorities.## Bayer undergoes layoffs as part of a company shake-up led by CEO Bill Anderson. FogPharma and ArtBio collaborate on designing a new radiopharma drug. Sands Capital raises a $555 million fund for biotech 'crossover' investing.## Big pharma companies pledge $2.16 billion in investments in France to boost global manufacturing and research capabilities. Interest grows in cancer vaccines as a potential breakthrough in immunotherapy.## Ascension confirms a ransomware attack leaving its computer systems offline. Insurers see elevated utilization in Q1 with minimal financial impact from cyberattacks.## The biotech industry sees a surge in cell and gene therapy technologies with biosimilar uptake showing mixed results. Novartis' biosimilar sales grow while Boehringer Ingelheim's biosi